Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation (The ONE Study ) (DART)

Clinical Trial ID NCT02244801

PubWeight™ 5.63^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02244801

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	The fate of skin homografts in man.	J Anat	1943	17.30
2	The behaviour and fate of skin autografts and skin homografts in rabbits: A report to the War Wounds Committee of the Medical Research Council.	J Anat	1944	16.73
3	ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group.	Stat Med	1999	7.32
4	Immunosuppressive drugs for kidney transplantation.	N Engl J Med	2004	4.09
5	Transplantation--a medical miracle of the 20th century.	N Engl J Med	2004	2.74
6	Transplantation 50 years later--progress, challenges, and promises.	N Engl J Med	2004	1.86
7	Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation.	Sci Transl Med	2015	1.04
8	Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based Therapy.	Front Immunol	2015	0.86
9	New insights into the mechanisms of Treg function.	Curr Opin Organ Transplant	2015	0.80
10	Exploratory clinical trials: implementation modes & guidelines, scope and regulatory framework.	Therapie	2009	0.78
11	Cell therapy to induce allograft tolerance: time to switch to plan B?	Front Immunol	2015	0.77
12	Regulatory T Cell Infusion Can Enhance Memory T Cell and Alloantibody Responses in Lymphodepleted Nonhuman Primate Heart Allograft Recipients.	Am J Transplant	2016	0.76
13	Clinical Potential of Regulatory T Cell Therapy in Liver Diseases: An Overview and Current Perspectives.	Front Immunol	2016	0.75
14	What Is Direct Allorecognition?	Curr Transplant Rep	2016	0.75